Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer

Objective This study aimed to identify patients at a high risk of recurrence using preoperative high-resolution computed tomography (HRCT) in clinical stage I non-small cell lung cancer (NSCLC). Methods A total of 567 patients who underwent screening and 1,216 who underwent external validation for clinical stage I NSCLC underwent lobectomy or segmentectomy. Staging was used on the basis of the 8th edition of the tumor–node–metastasis classification. Recurrence-free survival (RFS) was estimated using the Kaplan–Meier method, and the multivariable Cox proportional hazards model was used to identify independent prognostic factors for RFS. Results A multivariable Cox analysis identified solid component size (hazard ratio [HR], 1.66; 95% confidence interval [CI] 1.30–2.12; P < 0.001) and pure solid type (HR, 1.82; 95% CI 1.11–2.96; P = 0.017) on HRCT findings as independent prognostic factors for RFS. When patients were divided into high-risk (n = 331; solid component size of >2 cm or pure solid type) and low-risk (n = 236; solid component size of ≤2 cm and part solid type) groups, there was a significant difference in RFS (HR, 5.33; 95% CI 3.09–9.19; 5-year RFS, 69.8% vs. 92.9%, respectively; P < 0.001). This was confirmed in the validation set (HR, 5.32; 95% CI 3.61–7.85; 5-year RFS, 72.0% vs. 94.8%, respectively; P < 0.001). Conclusions In clinical stage I NSCLC, patients with a solid component size of >2 cm or pure solid type on HRCT were at a high risk of recurrence.

[1]  Kenji Suzuki,et al.  Preoperative nivolumab to evaluate pathological response in patients with stage I non-small cell lung cancer: a study protocol of phase II trial (POTENTIAL) , 2021, BMJ Open.

[2]  M. Okada,et al.  Prediction of lymph node metastasis using semiquantitative evaluation of PET for lung adenocarcinoma. , 2020, The Annals of thoracic surgery.

[3]  Kenji Suzuki,et al.  Prognostic impact of a ground-glass opacity component in clinical stage IA non-small cell lung cancer. , 2020, The Journal of thoracic and cardiovascular surgery.

[4]  M. Okada,et al.  Solid tumor size of 2 cm divides outcomes of patients with mixed ground glass opacity lung tumors. , 2020, The Annals of thoracic surgery.

[5]  E. Miyaoka,et al.  Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010 , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Takuo Hayashi,et al.  Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  M. Oudkerk,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  A. Nicholson,et al.  The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part‐Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  M. Okada,et al.  Prognostic role of positron emission tomography and high-resolution computed tomography in clinical stage IA lung adenocarcinoma. , 2013, The Annals of thoracic surgery.

[11]  Y. Takeshima,et al.  The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma. , 2013, The Journal of thoracic and cardiovascular surgery.

[12]  M. Okada,et al.  Solid tumor size on high-resolution computed tomography and maximum standardized uptake on positron emission tomography for new clinical T descriptors with T1 lung adenocarcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  T. Yamanaka,et al.  Solid tumors versus mixed tumors with a ground-glass opacity component in patients with clinical stage IA lung adenocarcinoma: prognostic comparison using high-resolution computed tomography findings. , 2013, The Journal of thoracic and cardiovascular surgery.

[14]  Kenji Suzuki,et al.  The size of consolidation on thin-section computed tomography is a better predictor of survival than the maximum tumour dimension in resectable lung cancer. , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[15]  K. Nagayama,et al.  The ground glass opacity component can be eliminated from the T-factor assessment of lung adenocarcinoma. , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[16]  M. Okada,et al.  Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: a multicenter study. , 2012, The Journal of thoracic and cardiovascular surgery.

[17]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[18]  Michael K Gould,et al.  PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer. , 2010, Chest.

[19]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.